These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38509167)

  • 21. Intranasal delivery of an adenovirus-vector vaccine co-expressing a modified spike protein and a genetic adjuvant confers lasting mucosal immunity against SARS-CoV-2.
    Jung HE; Ku KB; Kang BH; Park JH; Kim HC; Kim KD; Lee HK
    Antiviral Res; 2023 Aug; 216():105656. PubMed ID: 37327877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents.
    Bošnjak B; Odak I; Barros-Martins J; Sandrock I; Hammerschmidt SI; Permanyer M; Patzer GE; Greorgiev H; Gutierrez Jauregui R; Tscherne A; Schwarz JH; Kalodimou G; Ssebyatika G; Ciurkiewicz M; Willenzon S; Bubke A; Ristenpart J; Ritter C; Tuchel T; Meyer Zu Natrup C; Shin DL; Clever S; Limpinsel L; Baumgärtner W; Krey T; Volz A; Sutter G; Förster R
    Front Immunol; 2021; 12():772240. PubMed ID: 34858430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.
    Quan FS; Huang C; Compans RW; Kang SM
    J Virol; 2007 Apr; 81(7):3514-24. PubMed ID: 17251294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice.
    Li X; Wang L; Liu J; Fang E; Liu X; Peng Q; Zhang Z; Li M; Liu X; Wu X; Zhao D; Yang L; Li J; Cao S; Huang Y; Shi L; Xu H; Wang Y; Suo Y; Yue G; Nie J; Huang W; Li W; Li Y
    Emerg Microbes Infect; 2022 Dec; 11(1):1890-1899. PubMed ID: 35775819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SARS-CoV-2 spike-FLIPr fusion protein plus lipidated FLIPr protects against various SARS-CoV-2 variants in hamsters.
    Hsieh M-S; Hsu C-W; Liao H-C; Lin C-L; Chiang C-Y; Chen M-Y; Liu S-J; Liao C-L; Chen H-W
    J Virol; 2024 Feb; 98(2):e0154623. PubMed ID: 38299865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human immune responses elicited by an intranasal inactivated H5 influenza vaccine.
    Ainai A; van Riet E; Ito R; Ikeda K; Senchi K; Suzuki T; Tamura SI; Asanuma H; Odagiri T; Tashiro M; Kurata T; Multihartina P; Setiawaty V; Pangesti KNA; Hasegawa H
    Microbiol Immunol; 2020 Apr; 64(4):313-325. PubMed ID: 31957054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse.
    Du Y; Xu Y; Feng J; Hu L; Zhang Y; Zhang B; Guo W; Mai R; Chen L; Fang J; Zhang H; Peng T
    Vaccine; 2021 Apr; 39(16):2280-2287. PubMed ID: 33731271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants.
    Lei H; Alu A; Yang J; Ren W; He C; Lan T; He X; Yang L; Li J; Wang Z; Song X; Wang W; Lu G; Wei X
    Signal Transduct Target Ther; 2022 May; 7(1):159. PubMed ID: 35581200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral Immunization with rVSV Bivalent Vaccine Elicits Protective Immune Responses, Including ADCC, against Both SARS-CoV-2 and Influenza A Viruses.
    Ouyang MJ; Ao Z; Olukitibi TA; Lawrynuik P; Shieh C; Kung SKP; Fowke KR; Kobasa D; Yao X
    Vaccines (Basel); 2023 Aug; 11(9):. PubMed ID: 37766083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-clinical immunogenicity, biodistribution and toxicology evaluation of a chimpanzee adenovirus-based COVID-19 vaccine in rat and rhesus macaque.
    Dai X; Zhao W; Tong X; Liu W; Zeng X; Duan X; Wu H; Wang L; Huang Z; Tang X; Yang Y
    Arch Toxicol; 2022 May; 96(5):1437-1453. PubMed ID: 35226134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 in mice.
    King RG; Silva-Sanchez A; Peel JN; Botta D; Meza-Perez S; Allie R; Schultz MD; Liu M; Bradley JE; Qiu S; Yang G; Zhou F; Zumaquero E; Simpler TS; Mousseau B; Killian JT; Dean B; Shang Q; Tipper JL; Risley C; Harrod KS; Feng R; Lee Y; Shiberu B; Krishnan V; Peguillet I; Zhang J; Green T; Randall TD; Georges B; Lund FE; Roberts S
    bioRxiv; 2020 Oct; ():. PubMed ID: 33052351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2.
    Afkhami S; D'Agostino MR; Zhang A; Stacey HD; Marzok A; Kang A; Singh R; Bavananthasivam J; Ye G; Luo X; Wang F; Ang JC; Zganiacz A; Sankar U; Kazhdan N; Koenig JFE; Phelps A; Gameiro SF; Tang S; Jordana M; Wan Y; Mossman KL; Jeyanathan M; Gillgrass A; Medina MFC; Smaill F; Lichty BD; Miller MS; Xing Z
    Cell; 2022 Mar; 185(5):896-915.e19. PubMed ID: 35180381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.
    Hemmi T; Ainai A; Hashiguchi T; Tobiume M; Kanno T; Iwata-Yoshikawa N; Iida S; Sato Y; Miyamoto S; Ueno A; Sano K; Saito S; Shiwa-Sudo N; Nagata N; Tamura K; Suzuki R; Hasegawa H; Suzuki T
    Vaccine; 2022 Sep; 40(41):5892-5903. PubMed ID: 36064667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.
    Americo JL; Cotter CA; Earl PL; Liu R; Moss B
    Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2202069119. PubMed ID: 35679343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.
    Du L; Zhao G; Lin Y; Sui H; Chan C; Ma S; He Y; Jiang S; Wu C; Yuen KY; Jin DY; Zhou Y; Zheng BJ
    J Immunol; 2008 Jan; 180(2):948-56. PubMed ID: 18178835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice.
    Lu B; Huang Y; Huang L; Li B; Zheng Z; Chen Z; Chen J; Hu Q; Wang H
    Immunology; 2010 Jun; 130(2):254-61. PubMed ID: 20406307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of Systemic and Mucosal Humoral Immune Responses to an Adjuvanted Intranasal SARS-CoV-2 Protein Subunit Vaccine Candidate in Mice.
    Maltseva M; Galipeau Y; Renner TM; Deschatelets L; Durocher Y; Akache B; Langlois MA
    Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679875
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of neutralizing antibodies and mucosal IgA through intranasal immunization with the receptor binding domain of SARS-CoV-2 spike protein fused with the type IIb E. coli heat-labile enterotoxin A subunit.
    Hsieh HC; Chen CC; Chou PH; Liu WC; Wu SC
    Antiviral Res; 2023 Dec; 220():105752. PubMed ID: 37949318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ChAdOx1-S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination.
    Cokarić Brdovčak M; Materljan J; Šustić M; Ravlić S; Ružić T; Lisnić B; Miklić K; Brizić I; Pribanić Matešić M; Juranić Lisnić V; Halassy B; Rončević D; Knežević Z; Štefan L; Bertoglio F; Schubert M; Čičin-Šain L; Markotić A; Jonjić S; Krmpotić A
    Eur J Immunol; 2022 Jun; 52(6):936-945. PubMed ID: 35304741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.